<description>&lt;p&gt;Interview with Richard B. Lipton, MD, author of Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. Hosted by Cynthia E. Armand, MD.&lt;br /&gt; &lt;br /&gt; &lt;strong&gt;Related Content:&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt; &lt;li&gt;&lt;a class="related-article" href= "https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.0806?utm_source=podcast_platforms&amp;utm_medium=referral&amp;utm_campaign=related_article_links" target="_blank" rel="noopener"&gt;Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt;</description>

JAMA Neurology Author Interviews

JAMA Network

Fremanezumab for the Treatment of Migraine and Major Depressive Disorder

MAY 5, 202521 MIN
JAMA Neurology Author Interviews

Fremanezumab for the Treatment of Migraine and Major Depressive Disorder

MAY 5, 202521 MIN

Description

Interview with Richard B. Lipton, MD, author of Fremanezumab for the Treatment of Patients With Migraine and Comorbid Major Depressive Disorder. Hosted by Cynthia E. Armand, MD. Related Content: